PolyPeptide Group AG (LON:0AAJ)

Market Cap	823.16M +78.8%
Revenue (ttm)	339.64M +15.6%
Net Income	-18.47M
EPS	-0.56
Shares Out	n/a
PE Ratio	n/a
Forward PE	94.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,589
Average Volume	54,574
Open	27.50
Previous Close	27.40
Day's Range	26.30 - 27.90
52-Week Range	13.82 - 32.65
Beta	1.08
RSI	56.61
Earnings Date	Mar 12, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1952
• Employees: 1,440
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0AAJ

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR